SPEER-4A Inhibitors
SPEER-4A (Small Protein Enhancer of E3 RING [Really Interesting New Gene] Ligases-4A) inhibitors represent a specific category of chemical compounds that interact with the ubiquitin-proteasome system (UPS). The UPS is an intricate network within cells responsible for protein degradation and turnover, which is essential for maintaining cellular homeostasis. Within the UPS, E3 ligases are a critical component that mediates the transfer of ubiquitin to specific substrate proteins, tagging them for degradation. SPEER-4A inhibitors are designed to modulate the activity of a subset of E3 ligases. These chemical entities selectively bind to the E3 ligases and alter their conformation or activity. By doing so, they can influence the ubiquitination process, which can affect the stability and levels of various proteins within the cell.
SPEER-4A inhibitors are synthetically crafted molecules that usually possess high specificity for their target ligases. Their structure and function are the results of extensive research into the mechanisms of protein-protein interactions and the regulation of protein degradation. The design of these inhibitors often involves the identification of key binding domains within the E3 ligases, allowing for a tailored interaction that can effectively modulate the ligase's activity. The precise modulation of E3 ligases by SPEER-4A inhibitors represents a sophisticated approach to influencing the UPS. This is achieved by either inhibiting or potentially altering the ligase's activity to affect downstream processes within the cell. These inhibitors are typically the product of iterative optimization processes, where structure-activity relationship (SAR) studies guide the modification of molecular frameworks to enhance selectivity and potency.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, LY294002 leads to the blockade of the PI3K/AKT pathway. Since SPEER-4A's activity could be regulated by phosphorylation events downstream of PI3K, LY294002 indirectly inhibits SPEER-4A by preventing its activation through phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which subsequently blocks the ERK/MAPK pathway. If SPEER-4A is involved in this signaling cascade, its functional activity would be indirectly inhibited due to the suppression of ERK-mediated processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 could indirectly affect SPEER-4A's role, if any, in stress response or inflammatory pathways mediated by p38 MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 would lead to the attenuation of the JNK signaling pathway. SPEER-4A, if involved in JNK-mediated cellular responses, would have decreased activity due to this inhibition. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
This compound is a potent inhibitor of RAF kinases which are upstream of the MEK/ERK pathway. Inhibition of RAF would lead to decreased MEK/ERK signaling, potentially reducing SPEER-4A's activity if it is modulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of mTOR, which is part of the PI3K/AKT pathway. By inhibiting mTOR, SPEER-4A's function may be indirectly downregulated if it is under the control of mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, Wortmannin, would decrease AKT phosphorylation and activity, potentially leading to reduced SPEER-4A activity if it is regulated by the PI3K/AKT signaling pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. If SPEER-4A is activated by Src-mediated signaling, its activity would be indirectly inhibited by blocking Src kinase activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This MEK inhibitor prevents the activation of downstream ERK. If SPEER-4A's function is ERK-dependent, U0126 would lead to the functional inhibition of SPEER-4A. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation. If SPEER-4A is involved in NF-κB signaling pathways, its activity would be indirectly inhibited. | ||||||